EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

Are evidence-based guidelines translating into clinical practice? A national population-based study of the use of treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC) in England

Joanna Dodkins, Adrian Cook, Emily Mayne, Marina Parry, Matthew G Parry, Jemma Boyle, Julie Nossiter, Thomas E Cowling, Alison Tree, Noel Clarke, Jan van der Meulen, Ajay Aggarwal

European Journal of Cancer · 2025

DOI: 10.1016/j.ejca.2025.115335 ↗

Kurz gefasst

Leitlinie in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Joanna Dodkins und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Cancer Audit Collaborating Centre, Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK; Department of Health Servi…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Practice Guidelines as Topic, Androgen Antagonists, Practice Patterns, Physicians'. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Healthcare Quality Improvement Partnership, Llywodraeth Cymru, Heart of England NHS Foundation Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: International guidelines recommend treatment intensification combining docetaxel or androgen receptor pathway inhibitors with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer (mHSPC). However, evidence suggests underuse in many high-income countries. This study evaluates the use of treatment intensification in the English National Health Service (NHS) and explores patient and hospital-level factors associated with variation. METHODS: All men diagnosed with mHSPC in England between January 2018 and December 2022 were identified through the national cancer registry. Treatment intensification within six months of diagnosis was assessed using hospital and systemic anti-cancer therapy data. Multilevel regression models explored associations between treatment intensification and sociodemographic factors including age, comorbidities, frailty, ethnicity, socioeconomic status, rurality, and year of diagnosis. Variation among the 47 specialist multidisciplinary teams (sMDTs), responsible for coordinating prostate cancer care in England, was also evaluated. KEY FINDINGS AND LIMITATIONS: Among 29,713 mHSPC patients, treatment intensification use was 39.0 %. Treatment intensification use decreased with age, comorbidities, frailty, socioeconomic deprivation, and among black patients (p always < 0.05). 59.8 % (n = 9184) of men aged 75 or younger had a record of treatment intensification, compared to only 16.8 % (n = 2404) of men older than 75. The use of treatment intensification across sMDTs ranged from 20.3 % to 53.7 %, with greater variation in older patients, particularly those older than 75. CONCLUSIONS AND CLINICAL IMPLICATIONS: There is potential underuse of treatment intensification for mHSPC patients, particularly among older, black, and socioeconomically deprived patients. Significant variation in practice exists between specialist prostate cancer teams (sMDTs) nationally, especially in older populations, indicating that many patients may not receive optimal care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsPractice Guidelines as TopicAndrogen AntagonistsPractice Patterns, Physicians'HumansMaleAgedEnglandMiddle AgedAged, 80 and overRegistriesGuideline Adherence

Stichwörter der Autor:innen

CancerIntensificationMetastaticProstateTreatmentUtilisation

Substanzen

Androgen Antagonists

Autor:innen und Institutionen

  • National Cancer Audit Collaborating Centre, Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK; Department of Health Services Research & Policy, London School of Hygiene & Tropical Medicine, L…
  • National Cancer Audit Collaborating Centre, Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK.
  • The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, UK.
  • The Christie and Salford Royal NHS Trusts, Manchester, Manchester, UK.

Förderung

  • Healthcare Quality Improvement Partnership
  • Llywodraeth Cymru
  • Heart of England NHS Foundation Trust
  • National Institute for Health and Care Research

Zitieren

APA

Dodkins, J., Cook, A., Mayne, E., Parry, M., Parry, M. G., Boyle, J., Nossiter, J., Cowling, T. E., Tree, A., Clarke, N., van der Meulen, J., & Aggarwal, A. (2025). Are evidence-based guidelines translating into clinical practice? A national population-based study of the use of treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC) in England. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115335

Vancouver

Dodkins J, Cook A, Mayne E, Parry M, Parry MG, Boyle J, et al. Are evidence-based guidelines translating into clinical practice? A national population-based study of the use of treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC) in England. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115335

BibTeX
@article{Dodkins2025,
  author = {Dodkins, Joanna and Cook, Adrian and Mayne, Emily and Parry, Marina and Parry, Matthew G and Boyle, Jemma and Nossiter, Julie and Cowling, Thomas E and Tree, Alison and Clarke, Noel and van der Meulen, Jan and Aggarwal, Ajay},
  title = {Are evidence-based guidelines translating into clinical practice? A national population-based study of the use of treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC) in England},
  journal = {European Journal of Cancer},
  year = {2025},
  doi = {10.1016/j.ejca.2025.115335}
}
Kostenlos starten →